Trial · NCT04972123

The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope

NCT04972123, Phase 2, Completed, University of Wisconsin, Madison; results first posted 2024-06-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope. Trials, record NCT04972123. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04972123

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
NCT number: NCT04972123
Status: Completed
Phases: Phase 2
Enrollment: 143 participants, actual
Lead sponsor: University of Wisconsin, Madison
Conditions: Syncope, Vasovagal
Interventions: CPC - Capsaicin, Phenylephrine, Caffeine, Tilt Table Test, Placebo
First posted: 2021-07-22
Last updated: 2024-07-17
Results first posted: 2024-06-24

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test	During tilt table testing (up to approximately 35 minutes)	Hypotensive syncope is defined as transient loss of consciousness associated with SBP less than or equal to 90 mmHg. Near syncope is defined as sensation of "near fainting" while still being responsive to verbal commands. Near syncope will be used as a primary endpoint only when it is associated with a SBP less than or equal to 70 mmHg.
Primary	Time to Syncope or Near-syncope After CPC or Placebo Administration	During tilt table testing (up to approximately 35 minutes)	Time in seconds from CPC or Placebo administration to syncope or near syncope in patients who had an event
Secondary	Percentage of Patients Who Have Asystolic Pauses > 3 Seconds in the CPC and Placebo Arms	During tilt table testing (up to approximately 35 minutes)	Percentage of Participants with an event who had asystolic pauses \> 3 seconds during syncope or near syncope
Secondary	Fatigue Scores at 1, 4, and 8 Hours Post Tilt Table Testing	Up to 8 hours after tilt table testing (up to approximately 8 hours and 35 minutes)	Fatigue Scores at 1, 4 and 8 hours post tilt table testing in participants who had an event. Using standard continuous fatigue scale of 1 to 5, with 1 = no fatigue and 5 = max fatigue.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test	During tilt table testing (up to approximately 35 minutes)	Intention to treat based on randomized treatment assignment	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Time to Syncope or Near-syncope After CPC or Placebo Administration	During tilt table testing (up to approximately 35 minutes)	Secondary endpoints analyses were limited to participants who had syncope or near syncope	seconds	MEDIAN
SECONDARY	Percentage of Patients Who Have Asystolic Pauses > 3 Seconds in the CPC and Placebo Arms	During tilt table testing (up to approximately 35 minutes)	Secondary endpoints analyses were limited to participants who had syncope or near syncope	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Fatigue Scores at 1, 4, and 8 Hours Post Tilt Table Testing	Up to 8 hours after tilt table testing (up to approximately 8 hours and 35 minutes)	Secondary endpoints analyses were limited to participants who had syncope or near syncope	Score on a scale	MEDIAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test	CPC Adminstration	Number of participants with syncope or near syncope event	32		Participants
Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test	Placebo Administration	Number of participants with syncope or near syncope event	27		Participants
Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test	CPC Adminstration	Number of participants without syncope or near syncope event	33		Participants
Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test	Placebo Administration	Number of participants without syncope or near syncope event	35		Participants
Time to Syncope or Near-syncope After CPC or Placebo Administration	CPC Administration		90.1	Standard Deviation 95.0	seconds
Time to Syncope or Near-syncope After CPC or Placebo Administration	Placebo Administration		76.9	Standard Deviation 95.0	seconds
Percentage of Patients Who Have Asystolic Pauses > 3 Seconds in the CPC and Placebo Arms	CPC Administration		2		Participants
Percentage of Patients Who Have Asystolic Pauses > 3 Seconds in the CPC and Placebo Arms	Placebo Administration		1		Participants
Fatigue Scores at 1, 4, and 8 Hours Post Tilt Table Testing	CPC Adminstration	Fatigue rated at 1 hour post tilt test	2.2	Standard Deviation 1.05	Score on a scale
Fatigue Scores at 1, 4, and 8 Hours Post Tilt Table Testing	Placebo Administration	Fatigue rated at 1 hour post tilt test	2.0	Standard Deviation 0.85	Score on a scale

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow10

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	CPC Adminstration	66
Overall Study	STARTED	Placebo Adminstration	63
Overall Study	Primary Analysis Population	CPC Adminstration	65
Overall Study	Primary Analysis Population	Placebo Adminstration	62
Overall Study	Secondary Analysis Population	CPC Adminstration	32
Overall Study	Secondary Analysis Population	Placebo Adminstration	27
Overall Study	COMPLETED	CPC Adminstration	66
Overall Study	COMPLETED	Placebo Adminstration	63
Overall Study	NOT COMPLETED	CPC Adminstration	0
Overall Study	NOT COMPLETED	Placebo Adminstration	0

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain upper	Gastrointestinal disorders	CPC Adminstration	2	66	2
other	Abdominal pain upper	Gastrointestinal disorders	Placebo Administration	0	63	0
other	Nausea	Gastrointestinal disorders	CPC Adminstration	1	66	1
other	Nausea	Gastrointestinal disorders	Placebo Administration	0	63	0
other	Headache	Nervous system disorders	CPC Adminstration	1	66	1
other	Headache	Nervous system disorders	Placebo Administration	3	63	3
other	Migraine Headache	Nervous system disorders	CPC Adminstration	0	66	0
other	Migraine Headache	Nervous system disorders	Placebo Administration	1	63	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	CPC Adminstration	0	66
Total, all-cause mortality	Placebo Administration	0	63
Total, other adverse events	CPC Adminstration	3	66
Total, other adverse events	Placebo Administration	4	63
Total, serious adverse events	CPC Adminstration	0	66
Total, serious adverse events	Placebo Administration	0	63

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
11194602	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
CPC Administration vs Placebo Administration: Percentage of Patients Who Have Asystolic Pauses > 3 Seconds in the CPC and Placebo Arms	Trial comparisons
CPC Adminstration vs Placebo Administration: deaths from any cause	Trial comparisons
CPC Adminstration vs Placebo Administration: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04972123

GET https://conductscience.org/api/trials/v1/NCT04972123/registered

API reference For AI assistants